Advertisement

Rheumatology International

, Volume 30, Issue 8, pp 1121–1124 | Cite as

Altered cytokine profiles of mononuclear cells after stimulation in a patient with Blau syndrome

  • SangWook Son
  • JangHoon Lee
  • Chan-Wook Woo
  • IlHwan Kim
  • YoungChul Kye
  • KwangChul Lee
  • JungHwa LeeEmail author
Short Communication

Abstract

Autoinflammatory Blau syndrome (BS) is associated with NOD2 gene mutations that lead to constitutive NFκB activation. NOD2 functions as an intracellular receptor for the muramyl dipeptide (MDP) component of peptidoglycan (PGN). The objectives of this study are to analyse whether NFκB activation in BS affects immune cell functions, and whether NOD2 and toll-like receptor (TLR) pathways interact. Peripheral blood mononuclear cells (MNCs) from a BS patient and three normal donors were analyzed for their ability to produce pro- and anti-inflammatory cytokines in the presence and absence of MDP, PGN, and lipopolysaccharide (LPS). The results obtained showed that the basal TNF-α and IL-10 production by MNCs over 24 h of incubation was very low for both the patient and the normal donors. However, upon stimulation with MDP, LPS, and PGN, the cells from the BS patient produced much lower levels of TNF-α, IL-10, G-CSF, and IFN-γ than the normal donor cells. We conclude that the pathogenic mechanism responsible for the chronic inflammation that characterizes BS may relate to the impaired production of both pro- and anti-inflammatory cytokines to stimuli. The NOD2 pathway possibly interacts with either the TLR2 or TLR4 pathways.

Keywords

Blau syndrome NOD2 Toll-like receptor NFkB Cytokines 

Notes

Acknowledgment

This study was supported by a grant from the Korea University.

Conflict of interest

None.

References

  1. 1.
    Ogura Y, Inohara N, Benito A et al (2001) Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 276:4812–4818CrossRefPubMedGoogle Scholar
  2. 2.
    Gutierrez O, Pipaon C, Inohara N et al (2002) Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. J Biol Chem 277:41701–41705CrossRefPubMedGoogle Scholar
  3. 3.
    Girardin SE, Boneca IG, Viala J et al (2003) Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278:8869–8872CrossRefPubMedGoogle Scholar
  4. 4.
    Netea MG, Ferwerda G, de Jong DJ et al (2005) Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol 174:6518–6523PubMedGoogle Scholar
  5. 5.
    Kambe N, Nishikomori R, Kanazawa N (2005) The cytosolic pattern-recognition receptor Nod2 and inflammatory granulomatous disorders. J Dermatol Sci 39:71–80CrossRefPubMedGoogle Scholar
  6. 6.
    Tanabe T, Chamaillard M, Ogura Y et al (2004) Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J 23:1587–1597CrossRefPubMedGoogle Scholar
  7. 7.
    Kanazawa N, Okafuji I, Kambe N et al (2005) Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 105:1195–1197CrossRefPubMedGoogle Scholar
  8. 8.
    Abraham C, Cho JH (2006) Functional consequences of NOD2 (CARD15) mutations. Inflamm Bowel Dis 12:641–650CrossRefPubMedGoogle Scholar
  9. 9.
    Kanazawa N, Matsushima S, Kambe N, Tachibana T, Nagai S, Miyachi Y (2004) Presence of a sporadic case of systemic granulomatosis syndrome with a CARD15 mutation. J Invest Dermatol 122:851–852CrossRefPubMedGoogle Scholar
  10. 10.
    Martin TM, Zhang Z, Kurz P et al (2009) The NOD2 Defect in Blau Syndrome Does Not Result in Excess Interleukin-1 Activity. Arthritis Rheum 60:611–618CrossRefPubMedGoogle Scholar
  11. 11.
    Kim TH, Payne U, Zhang X et al (2007) Altered host:pathogen interactions conferred by the Blau syndrome mutation of NOD2. Rheumatol Int 27:257–262CrossRefPubMedGoogle Scholar
  12. 12.
    Milman N, Andersen CB, Hansen A et al (2006) Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation. Apmis 114:912–919CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • SangWook Son
    • 2
    • 3
  • JangHoon Lee
    • 1
  • Chan-Wook Woo
    • 1
  • IlHwan Kim
    • 2
  • YoungChul Kye
    • 2
  • KwangChul Lee
    • 1
  • JungHwa Lee
    • 1
    Email author
  1. 1.Department of PediatricsKorea University Medical CenterAnsan-siRepublic of Korea
  2. 2.Department of DermatologyKorea University Medical CenterSeoulSouth Korea
  3. 3.Division of Brain Korea 21 Project for Biomedical ScienceKorea University Medical CenterSeoulSouth Korea

Personalised recommendations